The dream is becoming a reality.

Starting from 2023 and up to now, most patients in Ukraine with the F508del mutation and aged 6 years and over have already started therapy with a gene corrector.

The uniqueness of “Tricaft” lies in the fact that the drug normalizes the function of chloride channels of all cells that produce mucus, thereby eliminating the symptoms of cystic fibrosis.

And today we have another piece of good news! We, as Ukraine, have received permission to expand the list of dispensing of the drug “Tricaft” for Ukrainians, which is available in Ukraine. The permission is based on the successful completion of clinical trials among patients with rare mutations in European countries.

As a conclusion: updated instructions for use:
https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf